Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doloteffin
- Development stage
- Unknown
- Lead developer
- Ardeypharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doloteffin is a phyto-pharmaceutical (herbal extract) developed and marketed by Ardeypharm GmbH. The active ingredient is a dry extract derived from the secondary storage roots of *Harpagophytum procumbens* (devil's claw), standardized to contain the iridoid glycoside harpagoside as its primary active constituent. It is indicated for the treatment of painful musculoskeletal conditions, including osteoarthritis, lower back pain, and other inflammatory joint disorders. The therapeutic effect is attributed to the anti-inflammatory and analgesic properties of its constituents, which modulate inflammatory mediators such as leukotrienes and cytokines. Doloteffin is administered orally as film-coated tablets and is available in Germany as an approved medicinal product for locomotor and skeletal diseases.
- Brand names
- Doloteffin
- Other names
- Devil's claw extractHarpagophytum procumbens root extractHarpagophytum
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Doloteffin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doloteffin.